Abstract
BackgroundGlucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; however, its counter-protective effects have also been suggested in patients with heart failure and the clear explanation for its mechanisms have not yet been offered.MethodsThe effects of GLP-1 analog on cardiac function and energy metabolism, especially glycemic and lipid metabolisms were elucidated using non-diabetic J2N-k hamsters which showed spontaneous dilated cardiomyopathy. J2N-k hamsters were treated with PBS (HF group), low-dose (HF-L group) or high-dose liraglutide (HF-H group).ResultsIn failing heart, GLP-1 analog exerted further deteriorated cardiac function (e.g. positive and negative dP/dt; p = 0.01 and p = 0.002, respectively) with overt fibrosis and cardiac enlargement (heart/body weight, 5.7 ± 0.2 in HF group versus 7.6 ± 0.2 in HF-H group; p = 0.02). The protein expression of cardiac muscles indicated the energy starvation status. Indirect calorimetry showed that failing hearts consumed higher energy and carbohydrate than normal hearts; moreover, this tendency was augmented by GLP-1 analog administration. Upon 10% glucose solution loading with GLP-1 analog administration (HF-H-G group) as complementary experiments, the cardiac function and fibrosis significantly ameliorated, whereas carbohydrate utilization augmented further and lipid utilization reduced more. The prognosis of HF-H-G group also significantly improved (p = 0.025).ConclusionsGlucagon-like peptide-1 analog caused the relative but desperate shortage of glycemic energy source for the failing cardiac muscles and it may restrict ATP synthesis, resulting in cardiac function deterioration. Therefore, appropriate energy supply and amount of carbohydrate intake should be carefully considered when administrating incretin-related drugs to patients with heart failure.
Highlights
Glucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; its counter-protective effects have been suggested in patients with heart failure and the clear explanation for its mechanisms have not yet been offered
Cardiac dysfunction is further exacerbated by administration of GLP‐1 analog Table 1 shows the characteristics of healthy hamsters (J2N-n), those (J2N-k) developed genetically dilated cardiomyopathy (DCM) and heart failure (HF), and those treated with lowdose (HF-L) or high-dose (HF-H) liraglutide
The mechanism remains uncertain in failing hearts, metabolic preference of substrates has been generally considered to change from lipid utilization to carbohydrate utilization [16, 20], several researches elucidated malnutrition expressing that lower levels of low-density lipoprotein (LDL) cholesterol were correlated with worse HF prognosis
Summary
Glucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; its counter-protective effects have been suggested in patients with heart failure and the clear explanation for its mechanisms have not yet been offered. Glucagon-like peptide-1 is an incretin hormone, and its analogs and dipeptidyl peptidase-4 (DPP4) inhibitors have been widely used for the treatment of type 2 diabetes mellitus (T2DM) recently. The anti-oxidative and anti-inflammatory effects of the GLP-1 analog liraglutide have been reported in human umbilical vein endothelial. Heart failure (HF) increasingly occurred in patients treated with liraglutide [8] and DPP4 inhibitors in a large-scale clinical trial [9] and some meta-analyses [10, 11].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
